160 Parallel studies in humans could help form the rational basis for a more unified PD-L1 immunohistochemistry scoring approach. In conclusion, the recent success of immune-based cancer therapy ...
From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...
GlobalData on MSN13d
FDA expands Enhertu approval to include HER2-ultralow breast cancer patientsEnhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...
During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...
IHC: Immunohistochemistry; NSCLC: Non-small-cell lung cancer. Adapted with permission from [77]. The authors have no relevant affiliations or financial involvement with any organization or entity ...
operable [tumor stage T1 to T3 and nodal stage N0 or ... The 7-year invasive disease–free survival in the IHC 3+ cohorts (total, 1132 patients) was 82.8% with T-DM1 and 66.5% with trastuzumab ...
AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster ...
Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...
The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer, based on phase 3 DESTINY-Breast06 trial results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback